Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

PubWeight™: 0.80‹?›

🔗 View Article (PMC 4077353)

Published in J Immunol on January 08, 2014


Katelyn T Byrne1, Peisheng Zhang, Shannon M Steinberg, Mary Jo Turk

Author Affiliations

1: Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755.

Articles cited by this

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08

Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81

Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med (1997) 5.72

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature (1992) 5.47

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77

Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 3.63

Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity (2008) 3.33

Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med (2005) 3.10

Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65

Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med (2006) 2.55

Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol (1987) 2.51

Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med (2001) 2.49

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood (2000) 2.00

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol (2009) 1.55

Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A (2008) 1.49

Late priming and variability of epitope-specific CD8+ T cell responses during a persistent virus infection. J Immunol (2005) 1.47

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24

A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res (1996) 1.15

MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol (1999) 1.13

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03

Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol (2001) 1.03

Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol (2001) 1.00

Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93

Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res (2011) 0.90

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunol Immunother (2012) 0.87

Tissue destruction caused by cytotoxic T lymphocytes induces deletional tolerance. Proc Natl Acad Sci U S A (2009) 0.85

CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. J Immunol (2012) 0.81

Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells. PLoS One (2012) 0.78

Articles by these authors

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65

IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest (2006) 1.59

Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev (2004) 1.58

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43

Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol (2004) 1.35

Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol (2008) 1.27

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res (2007) 1.24

Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol (2006) 1.21

Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene (2003) 1.16

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol (2012) 1.16

New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15

A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09

Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res (2003) 1.07

Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res (2006) 1.04

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03

p38 MAP kinase regulation of oligodendrocyte differentiation with CREB as a potential target. Neurochem Res (2007) 0.97

Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96

Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93

Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res (2008) 0.92

Prostacyclin primes pregnant human myometrium for an enhanced contractile response in parturition. J Clin Invest (2008) 0.92

Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol (2003) 0.90

Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89

GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther (2002) 0.87

Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung (2013) 0.86

Synthesis and characterization of novel reversible photoswitchable fluorescent polymeric nanoparticles via one-step miniemulsion polymerization. J Phys Chem B (2011) 0.86

Clonal immortalized human glial cell lines support varying levels of JC virus infection due to differences in cellular gene expression. J Neuroimmune Pharmacol (2013) 0.86

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res (2014) 0.85

Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr Biol (Camb) (2013) 0.84

Three-dimensional culture of human uterine smooth muscle myocytes on a resorbable scaffolding. Tissue Eng (2003) 0.80

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79

Effects of thyroxine on cardiac function and lymphocyte beta-adrenoceptors in patients with chronic congestive heart failure. Chin Med J (Engl) (2003) 0.78

The signaling mechanisms of long distance intercellular calcium waves (far waves) in cultured human uterine myocytes. J Muscle Res Cell Motil (2002) 0.76

A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy. Chem Commun (Camb) (2015) 0.75

Design and synthesis of FRET-mediated multicolor and photoswitchable fluorescent polymer nanoparticles with tunable emission properties. J Phys Chem B (2012) 0.75

Ratiometric detection and imaging of endogenous hypochlorite in live cells and in vivo achieved by using an aggregation induced emission (AIE)-based nanoprobe. Chem Commun (Camb) (2016) 0.75